期刊文献+

多学科实施侵袭性术式在复发性卵巢癌二次肿瘤细胞减灭术中的意义 被引量:2

Value of multi-disciplinary cooperating in second cytoredutive surgery for recurrent epithelial carcinoma
原文传递
导出
摘要 目的探讨复发性卵巢上皮癌二次肿瘤细胞减灭术中实施侵袭性术式的必要性及多学科手术团队参与的意义。方法收集郑州大学附属肿瘤医院妇瘤科接受二次肿瘤细胞减灭术复发性卵巢上皮癌患者的临床及手术资料,共62例,依据手术团队学科组成分为两组:妇瘤科手术组18例,妇瘤科与胃肠、肝胆外科医师多学科手术组44例。依据术中发现,评估清除所有病灶时所需侵袭性手术例次;比较2组实际侵袭性术式实施例数、减瘤结局及手术并发症。结果依术中发现评估,7例(11.3%)无需侵袭性手术、47例(75.8%)需要83例次侵袭性手术方式可达到肉眼无瘤。两组围手术期均无死亡病例。结论复发性卵巢癌二次肿瘤细胞减灭术以肉眼无瘤为减瘤目标,多需实施上腹部脏器及结直肠切除的侵袭性手术方式,多学科共同施术是获得理想手术结局的保证。 Objective To investigate the value of multi- disciplinary approach in second cytoredutive surgery for recurrent epithelial carcinoma. Methods The retrospective study included 62 patients with recurrent ovarian epithelial carcinoma who received second cytoreductive surgery. According to different surgical team,all patients were devided into two groups. 44 patients received surgeries with gynecological oncologists and general surgeons or hepatobilliary surgeons as multi- disciplinary group; 18 patients received surgeries with gynecological oncologists only as gynecological group.Based on surgical exploration,necessary aggressive surgical procedures during second cytoreduction in each patient for removal all gross recurrent diseases were estimated. Actural surgical procedures and surgical outcomes in all patient during second cytoredutive surgery were analyzed in detail. Results It was estimated that 47( 75. 8%) patients need 83 times of aggressive surgical procedures to remove all gross diseases,only 7( 11. 3%) patients can achieve no residual diseases without aggressive surgical procedures. Conclusion Aggressive surgery may be always necessary to removal all diseases in second cytoreductive surgery for recurrent epithelial ovarian cancer. Multi- discioplinary surgical team is more suitable to carry it out successfully than gynecological oncologists alone.
出处 《医药论坛杂志》 2015年第8期45-47,共3页 Journal of Medical Forum
关键词 复发性卵巢上皮癌 二次肿瘤细胞减灭术 侵袭性手术方式 多学科手术模式 Recurrent epithelial carcinoma Second cytoreductive surgery Aggressive surgery Multi-disciplinary approach
  • 相关文献

参考文献6

  • 1Zang RY, Harter P, Chi DS, et al. Predictors of survival in pa- tients with recurrent ovarian cancer undergoing secondary cytore- ductive surgery based on the pooled analysis of an international collaborative cohort[ J]. Br J Cancer,2011, 105 (7) :890-896.
  • 2Chang S,I, Bristow RE, Ryu HS. Impact of complete cytoreduc- tion leaving no gross residual disease associated with radical cy- toreductive surgical procedures on survival in advanced ovarian cancer [ J]. Ann Surg Onco1,2012,19 ( 13 ) :4059-4067.
  • 3Aletti GD, Dowdy SC, Gostout BS, et al. Quality improvement in the surgical approach to advanced ovarian cancer: the Mayo Clinic experience[J]. J Am Coil Surg, 2009,208(4) :614-620.
  • 4马彧,李艺,崔恒,梁旭东,唐志坚,李小平,赵彦,魏丽惠.间歇性肿瘤细胞减灭术治疗晚期卵巢上皮性癌的再评价[J].中华妇产科杂志,2012,47(5):355-360. 被引量:7
  • 5Salani R, Santillan A, Zahurak ML, et al. Secondary cytoreduc- tive surgery for localized, recurrent epithelial ovarian cancer: a- nalysis of prognostic factors and survival outcome [ J ]. Cancer, 2007,109 (4):685-691.
  • 6曹泽毅.中华妇产科学[M].2版.北京:人民卫生出版社,2006:508-511.

二级参考文献12

  • 1Permuth-Wey J, Sellers TA. Epidemiology of ovarian cancer. Methods Mol Biol, 2009, 472:413-437.
  • 2Sehouli J, Konsgen D, Mustea A, et al. "IMO" :intraoperative mapping of ovarian cancer. Zentralb! Gynakol, 2003, 125:129- 135.
  • 3National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: ovarian cancer, including fallopian tube tumor and primary peritoneal cancer. Version 2. 2011. [EB/OL]. [2011-11-10]. http ://www. nccn.org/professionals/physician _ gls/f_guidelines. asp.
  • 4Hegazy MA, Hegazi RA, Elshafei MA, et al. Neoadjuvant chemotherapy versus primary surgery in advanced ovarian carcinoma. World J Surg Oncol, 2005, 3:57.
  • 5Lee SJ, Kim BG, Lee JW, et al. Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery. J Obstet Gynaecol Res, 2006, 32:99- 106.
  • 6Everett EN, French AE, Stone RL, et al. Initial chemotherapy followed by surgical cytoreduction for the treatment of stage Ⅲ/Ⅳ epithelial ovarian cancer. Am J Obstet Gynecol, 2006, 195:568- 574.
  • 7Inciura A, Simavicius A, Juozaityte E, et al. Comparison of adjuvant and neoadjuvant chemotherapy in the management of advanced ovarian cancer: a retrospective study of 574 patients. BMC Cancer, 2006, 6:153.
  • 8Covens AL. A critique of surgical cytoreduction in advanced ovarian cancer. Gynecol Oncol, 2000, 78:269-274.
  • 9van der Burg ME, van Lent M, Buyse M, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med, 1995, 332:629-634.
  • 10Rose PG, Nerenstone S, Brady MF, et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med, 2004, 35 1:2489-2497.

共引文献21

同被引文献8

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部